公开(公告)号：EP2386633A1

公开(公告)日：2011-11-16

申请号：EP10729253.4

申请日：2010-01-08

申请人： International Institute of Cancer Immunology, Inc.

发明人： SUGIYAMA, Haruo ,  OJI, Yusuke

IPC分类号： C12N15/00 ,  A61K31/713 ,  A61K39/00 ,  A61K48/00 ,  A61P35/00 ,  A61P43/00 ,  C12N15/09 ,  G01N33/53 ,  C07K14/82

CPC分类号： A61K39/0011 ,  A61K31/713 ,  A61K38/00 ,  A61K38/08 ,  C07K14/47 ,  C07K14/82 ,  C12N15/113 ,  C12N15/1135 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/531 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57484

摘要： The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject.

摘要翻译： 本发明提供使用各种癌症中表达的蛋白质检测癌症的方法，以及使用该蛋白质作为指标来治疗或预防这种癌症的药物组合物。 此外，本发明提供含有源自蛋白质的癌抗原肽的药物组合物。 更具体地，该方法包括确定从受试者获得的样品中eEF2多肽或eEF2抗体的存在或量的步骤。

公开(公告)号：EP2757373A1

公开(公告)日：2014-07-23

申请号：EP12832236.9

申请日：2012-09-13

申请人： International Institute of Cancer Immunology, Inc. ,  Otsuka Pharmaceutical Co., Ltd.

发明人： SUGIYAMA, Haruo ,  OJI, Yusuke ,  KATSURAGI, Kiyonori ,  TANAKA, Hideaki ,  SOGO, Shinji ,  GOTO, Yoshihiro ,  OHMOTO, Yasukazu ,  IWATA, Husako

IPC分类号： G01N33/53 ,  C07K14/82 ,  C12N15/09 ,  A61K39/00 ,  G01N33/574

CPC分类号： G01N33/574 ,  A61K39/0011 ,  C07K14/82 ,  G01N33/57407 ,  G01N33/57419 ,  G01N33/57426 ,  G01N33/57488 ,  G01N33/6854

摘要： Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method. The method for measuring an anti-WT1 antibody in a sample includes using a polypeptide having antigenicity to the anti-WT1 antibody selected from a polypeptide comprising the amino acid sequence of positions 294-449 in SEQ ID NO: 1, a partial polypeptide of the polypeptide, and a polypeptide including an amino acid sequence having deletion, substitution, or addition of one to several amino acids in the amino acid sequence constituting each of these polypeptides and/or a polypeptide having antigenicity to the anti-WT1 antibody selected from a polypeptide comprising the amino acid sequence of positions 181-324 in SEQ ID NO: 1, a partial polypeptide of the polypeptide, and a polypeptide including an amino acid sequence having deletion, substitution, or addition of one to several amino acids in the amino acid sequence constituting each of these polypeptides.

摘要翻译： 本发明涉及一种测定样品中的抗WT1抗体的方法的发明，其能够更准确地测定和评价抗WT1抗体并使用该方法。 用于测量样品中抗WT1抗体的方法包括使用对抗WT1抗体具有抗原性的多肽，所述抗WT1抗体选自包含SEQ ID NO：1中294-449位氨基酸序列的多肽， 多肽和包含在构成每个这些多肽的氨基酸序列中具有1至数个氨基酸的缺失，取代或添加的氨基酸序列的多肽和/或对抗WT1抗体具有抗原性的多肽，所述抗WT1抗体选自多肽 其包含SEQ ID NO：1中的位置181-324的氨基酸序列，多肽的部分多肽，以及包含在氨基酸序列中具有一至几个氨基酸的缺失，取代或添加的氨基酸序列的多肽 构成这些多肽中的每一种。

公开(公告)号：EP2998740A1

公开(公告)日：2016-03-23

申请号：EP14797083.4

申请日：2014-05-12

申请人： International Institute of Cancer Immunology, Inc.

发明人： SUGIYAMA, Haruo ,  OJI, Yusuke

IPC分类号： G01N33/53 ,  A61K39/00 ,  A61P35/00 ,  A61P35/02 ,  G01N33/574 ,  C07K7/08 ,  C07K14/82

CPC分类号： G01N33/57496 ,  C07K14/4748 ,  G01N33/57407 ,  G01N2333/47 ,  G01N2500/00

摘要： Provided is a method for predicting a clinical effect on a subject in a WT1 peptide immunotherapy, said method comprising: a) a step for contacting a sample derived from the subject with WT1 antigen peptide or a variant thereof; and b) a step for detecting the binding of the sample to the WT1 antigen peptide or a variant thereof and thus measuring anti-WT1 antigen peptide IgG antibody titer existing in the sample, characterized in that an increase in the anti-WT1 antigen peptide IgG antibody titer in the subject determines the achievement of a favorable clinical effect. Also provided is a kit for performing the method according to the present invention, said kit containing WT1 antigen peptide or a variant thereof.

摘要翻译： 本发明提供了一种用于预测WT1肽免疫治疗对受试者的临床效果的方法，所述方法包括：a）使来自受试者的样品与WT1抗原肽或其变体接触的步骤; 和b）检测样品与WT1抗原肽或其变体的结合并因此测量样品中存在的抗WT1抗原肽IgG抗体滴度的步骤，其特征在于抗WT1抗原肽IgG的增加 受试者的抗体效价决定了获得有利的临床效果。 还提供了用于进行根据本发明的方法的试剂盒，所述试剂盒含有WT1抗原肽或其变体。

公开(公告)号：EP2009100B1

公开(公告)日：2012-07-11

申请号：EP07740105.7

申请日：2007-03-28

申请人： International Institute of Cancer Immunology, Inc.

发明人： SUGIYAMA, Haruo ,  OJI, Yusuke

IPC分类号： A61K31/7088 ,  C12N15/113

CPC分类号： C12N15/1135 ,  C12N2310/14

摘要： Disclosed is a polynucleotide which comprises contiguous at least 15 nucleotides in the nucleotide sequence depicted in SEQ ID NO:26 and contains the nucleotide sequence depicted in SEQ ID NO:27. Also disclosed is siRNA produced based on the polynucleotide. A cancer cell-specific molecular-targeting therapy which can successfully control the function of WT1 can be realized.

公开(公告)号：EP2009100A1

公开(公告)日：2008-12-31

申请号：EP07740105.7

申请日：2007-03-28

申请人： International Institute of Cancer Immunology, Inc.

发明人： SUGIYAMA, Haruo ,  OJI, Yusuke

IPC分类号： C12N15/09

CPC分类号： C12N15/1135 ,  C12N2310/14

摘要： Disclosed is a polynucleotide having at least 15 contiguous bases in the base sequence of SEQ ID NO:26 and including the base sequence of SEQ ID NO:27. Also disclosed is siRNA produced based on the polynucleotide. By means of this, a cancer cell-specific molecular-targeted therapy, which successfully controls the function of WT1, can be realized.

摘要翻译： 公开了在SEQ ID NO：26的碱基序列中具有至少15个连续碱基且包含SEQ ID NO：27的碱基序列的多核苷酸。 还公开了基于多核苷酸产生的siRNA。 通过这种方式，可以实现成功控制WT1功能的癌细胞特异性分子靶向治疗。